A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation
Phase of Trial: Phase 0
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Ipilimumab (Primary) ; Lenalidomide (Primary)
- Indications B cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma
- Focus Adverse reactions
- 08 Dec 2017 Planned number of patients changed from 30 to 40.
- 08 Dec 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 08 Dec 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.